News >

Immunotherapy, PARP Inhibitors Picking Up Steam in TNBC Pipeline

Chelsea LoCascio
Published: Monday, Oct 30, 2017

Howard A. “Skip” Burris, MD

Howard A. “Skip” Burris, MD
Ongoing clinical trials are exploring novel approaches in triple-negative breast cancer (TNBC), such as PARP inhibition and immunotherapy.

Early promise has already been observed, as phase Ib/II findings found that a combination of eribulin (Halaven) and pembrolizumab (Keytruda) was associated with an objective response rate (ORR) of 41.2% for untreated patients with metastatic TNBC.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication